H.C. Wainwright raised the firm’s price target on Kala Pharmaceuticals to $20 from $12 and keeps a Buy rating on the shares following the 2022 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on KALA:
- Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Kala Pharmaceuticals reports Q4 EPS ($7.97) vs ($33.94) last year
- Kala recruiting for study of KPI-012 in participants with PCED
- Kala Pharmaceuticals files to sell up to $40M in common stock